MA52285A - Anticorps multispécifiques et leur utilisation - Google Patents

Anticorps multispécifiques et leur utilisation

Info

Publication number
MA52285A
MA52285A MA052285A MA52285A MA52285A MA 52285 A MA52285 A MA 52285A MA 052285 A MA052285 A MA 052285A MA 52285 A MA52285 A MA 52285A MA 52285 A MA52285 A MA 52285A
Authority
MA
Morocco
Prior art keywords
multispecific antibodies
multispecific
antibodies
Prior art date
Application number
MA052285A
Other languages
English (en)
Inventor
Alexander Bujotzek
Stefan Dengl
Sebastian Fenn
Jens Fischer
Silke Kirchner
Claudia Kirstenpfad
Stefan Klostermann
Meher Majety
Joerg Moelleken
Georg Tiefenthaler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA52285A publication Critical patent/MA52285A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA052285A 2018-04-18 2019-04-17 Anticorps multispécifiques et leur utilisation MA52285A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18168053 2018-04-18

Publications (1)

Publication Number Publication Date
MA52285A true MA52285A (fr) 2021-02-24

Family

ID=62025743

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052285A MA52285A (fr) 2018-04-18 2019-04-17 Anticorps multispécifiques et leur utilisation

Country Status (19)

Country Link
US (2) US20210147554A1 (fr)
EP (1) EP3781594A1 (fr)
JP (3) JP7724610B2 (fr)
KR (1) KR20210005639A (fr)
CN (1) CN111989343B (fr)
AR (1) AR115052A1 (fr)
AU (1) AU2019256744A1 (fr)
BR (1) BR112020021111A2 (fr)
CA (1) CA3095547A1 (fr)
CL (1) CL2020002539A1 (fr)
CO (1) CO2020012360A2 (fr)
IL (1) IL277559A (fr)
MA (1) MA52285A (fr)
MX (1) MX2020010946A (fr)
PE (1) PE20210517A1 (fr)
PH (1) PH12020500667A1 (fr)
SG (1) SG11202009692SA (fr)
TW (1) TW201945394A (fr)
WO (1) WO2019202041A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
CN113056483B (zh) 2018-07-09 2025-08-01 戊瑞治疗有限公司 结合到ilt4的抗体
CN113528448B (zh) * 2020-04-14 2023-01-24 同济大学 一种人胚胎干细胞的构建方法
MX2022015498A (es) * 2020-06-11 2023-01-24 Tizona Therapeutics Captadores de celulas inmunitarias biespecificas con especificidad de union para hla-g y otro antigeno.
KR20230041819A (ko) * 2020-07-29 2023-03-24 얀센 바이오테크 인코포레이티드 Hla-g 항원-결합 도메인을 포함하는 단백질 및 이의 용도
EP4245317A4 (fr) * 2020-11-10 2024-11-06 Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. Anticorps bispécifique pour claudin 18a2 et cd3 et application d'un anticorps bispécifique
MX2023007133A (es) * 2020-12-17 2023-06-27 Hoffmann La Roche Anticuerpos anti-hla-g y uso de estos.
US12012454B2 (en) * 2021-03-24 2024-06-18 China Medical University Hospital Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same
US11795227B2 (en) * 2021-03-24 2023-10-24 Shine-On Biomedical Co., Ltd. Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same
CN113398253B (zh) * 2021-05-14 2023-01-24 北京化工大学 β2微球蛋白聚集抑制剂
CA3221568A1 (fr) * 2021-05-26 2022-12-01 Board Of Regents, The University Of Texas System Recepteur antigenique chimerique pour cibler des cancers positifs a hla-g
TWI823402B (zh) * 2021-07-21 2023-11-21 長聖國際生技股份有限公司 多特異性單域抗體嵌合抗原受體及t細胞銜接體、核酸、其表達細胞、其用途以及治療癌症之醫藥組合物
WO2024188965A1 (fr) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Polythérapie utilisant un anticorps bispécifique pd1-lag3 et un anticorps bispécifique de lymphocytes t hla-g
EP4680638A1 (fr) 2023-03-13 2026-01-21 F. Hoffmann-La Roche AG Traitement du cancer à l'aide d'un anticorps bispécifique anti-hla-g/anti-cd3 et d'un agoniste de 4-1bb (cd137)
CN120682359A (zh) * 2024-03-21 2025-09-23 合肥天港免疫药物有限公司 双特异性抗体及其应用

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211999B2 (en) * 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0368684B2 (fr) 1988-11-11 2004-09-29 Medical Research Council Clonage de séquences d'immunoglobulines de domaines variables.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (fr) 1990-12-03 2003-02-04 Lisa J. Garrard Methode d'enrichissement de proteines variantes aux proprietes liantes alterees
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
EP1240319A1 (fr) 1999-12-15 2002-09-18 Genentech, Inc. Balayage aveugle, procede combinatoire permettant la representation d'epitopes de proteines fonctionnelles
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
AU2002228745A1 (en) 2000-10-23 2002-05-06 Rajagopalan, Sumati Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (fr) 2000-11-30 2011-11-22 Medarex, Inc. Rongeurs transgeniques et transchromosomiques pour la fabrication d'anticorps humains
CA2488441C (fr) 2002-06-03 2015-01-27 Genentech, Inc. Bibliotheques de phages et anticorps synthetiques
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
WO2004065416A2 (fr) 2003-01-16 2004-08-05 Genentech, Inc. Banques de phages anticorps synthetiques
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JP2008501621A (ja) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1740615B1 (fr) 2004-03-31 2014-11-05 Genentech, Inc. Anticorps anti-tgf-beta humanises
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
EP1940881B1 (fr) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973951A2 (fr) 2005-12-02 2008-10-01 Genentech, Inc. Polypeptides de liaison avec des sequences de diversite limitees
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
WO2008027236A2 (fr) 2006-08-30 2008-03-06 Genentech, Inc. Anticorps multispécifiques
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
CA2756244A1 (fr) 2009-04-02 2010-10-07 Roche Glycart Ag Anticorps multispecifiques renfermant des anticorps de longueur entiere et des fragments fab a chaine unique
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
WO2010129304A2 (fr) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP2478013B1 (fr) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Complexes protéiques contenant une super-hélice et/ou une attache et leurs utilisations
CA2785907A1 (fr) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Produits de recombinaison de liaison a ron et leurs procedes d'utilisation
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
NO2748201T3 (fr) 2011-08-23 2018-05-12
EP2748202B1 (fr) 2011-08-23 2018-07-04 Roche Glycart AG Molécules bispécifiques de liaison à un antigène
WO2013026839A1 (fr) * 2011-08-23 2013-02-28 Roche Glycart Ag Anticorps bispécifiques spécifiques pour les antigènes d'activation des lymphocytes t et un antigène tumoral et procédés d'utiliation correspondants
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
MX360352B (es) 2012-02-15 2018-10-30 Hoffmann La Roche Cromatografia de afinidad basada en receptores fc.
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
CN105849124B (zh) 2013-12-20 2022-04-12 豪夫迈·罗氏有限公司 双重特异性抗体
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
CN106795221B (zh) * 2014-04-03 2022-06-07 塞勒克提斯公司 用于癌症免疫治疗的cd33特异性嵌合抗原受体
EP3174897B1 (fr) 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Anticorps multi-spécifiques
EP3177643B1 (fr) 2014-08-04 2019-05-08 F.Hoffmann-La Roche Ag Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
ES2857553T3 (es) 2014-10-24 2021-09-29 Hoffmann La Roche Humanización de anticuerpos basada en ángulo interdominio VH-VL
AU2016243128A1 (en) * 2015-03-27 2017-11-02 University Of Southern California HLA-G as a novel target for CAR T-cell immunotherapy
WO2016172485A2 (fr) 2015-04-24 2016-10-27 Genentech, Inc. Protéines multispécifiques de liaison à l'antigène
AU2017272875B2 (en) 2016-06-03 2023-10-19 Invectys Anti HLA-G specific antibodies

Also Published As

Publication number Publication date
CA3095547A1 (fr) 2019-10-24
CN111989343B (zh) 2023-12-26
JP2021521785A (ja) 2021-08-30
SG11202009692SA (en) 2020-11-27
TW201945394A (zh) 2019-12-01
CO2020012360A2 (es) 2020-10-30
KR20210005639A (ko) 2021-01-14
US20250051455A1 (en) 2025-02-13
WO2019202041A1 (fr) 2019-10-24
AU2019256744A1 (en) 2020-11-19
JP2025118635A (ja) 2025-08-13
JP7724610B2 (ja) 2025-08-18
BR112020021111A2 (pt) 2021-02-17
AR115052A1 (es) 2020-11-25
IL277559A (en) 2020-11-30
JP2023081898A (ja) 2023-06-13
MX2020010946A (es) 2020-11-09
US20210147554A1 (en) 2021-05-20
CL2020002539A1 (es) 2021-01-22
EP3781594A1 (fr) 2021-02-24
PH12020500667A1 (en) 2021-07-26
CN111989343A (zh) 2020-11-24
PE20210517A1 (es) 2021-03-17

Similar Documents

Publication Publication Date Title
MA52285A (fr) Anticorps multispécifiques et leur utilisation
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
MA47311A (fr) Anticorps anti-tgf-bêta et leur utilisation
EP3904386A4 (fr) Anticorps et son utilisation
EP3802612A4 (fr) Anticorps anti-b7-h3 et son utilisation
EP3797124A4 (fr) Anticorps anti-ro1 et son utilisation
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
EP3887403A4 (fr) Anticorps anti-4-1bb et son utilisation
EP3442567A4 (fr) Anticorps anti-psma et leur utilisation
EP3731868A4 (fr) Anticorps anti-tigit et leur utilisation comme agents thérapeutiques et diagnostiques
EP3572427A4 (fr) Anticorps ciblant bcma et son utilisation
EP3907240A4 (fr) Anticorps anti-tnfr2 et son utilisation
EP3626825A4 (fr) Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament
EP3962956A4 (fr) Anticorps anti-hvem et leur utilisation
EP4039705A4 (fr) Anticorps ciblant bcma, anticorps bispécifique et leur utilisation
EP3575318A4 (fr) Anticorps anti-pd-1 et son utilisation
EP3604338A4 (fr) Anticorps anti-ox40 et utilisation correspondante
EP3875484A4 (fr) Anticorps ciblant cll1 et son utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
EP3733705A4 (fr) Anticorps monoclonaux et procédés de leur utilisation
EP3599249A4 (fr) Conjugué anticorps anti-5t4-médicament et son utilisation
EP3630844A4 (fr) Nouvel anticorps anti-c-met et son utilisation
MA50038A (fr) Anticorps anti-pd-l1 de et son utilisation